Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRADICAL: Radical-Dose IGRT + Immunotherapy in Metastatic NSCLC
NCT03176173Completed
- Sponsor
- Stanford University
- Start
- Jun 2017
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Open-label trial (2 arms), sponsored by Stanford University. Primary endpoint: Progression-free Survival at 24 weeks. Started Jun 2017; status: completed.
Beyond the preview
Go deeper on NCT03176173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176173.